A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Recruiting now · Phase 1
Conditions studied: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
In brief
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Key facts
- Study ID
- NCT06022029
- Run by
- OncoNano Medicine, Inc.
- People needed
- 168
- Starts
- 2023-10-13
- Expected to finish
- 2026-08-29
- Last updated by the study team
- 2025-12-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Ability to understand and willingness to sign written informed consent before performance of any study procedures
- Age ≥ 18 years
- Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists.
- Participants must have a minimum of one injectable and measurable lesion.
- Participants with prior Hepatitis B or C are eligible if they have adequate liver function
- Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load <400 copies/mL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells/uL
- Adequate bone marrow function:
- Adequate liver function
- Exclusion Criteria: Patients will be excluded from this study if they meet any of the following criteria (Part 1a and Part 1b).
- Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy.
- Major surgery within 4 weeks before the first dose of study drug.
- Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion.
- Prolongation of corrected QT (QTc) interval to >470 millisecond (ms) for males and females when electrolytes balance is normal.
- Females who are breastfeeding or pregnant at screening or baseline
- Females of childbearing potential that refuse to use a highly effective method of contraception.
- Has uncontrolled or poorly controlled hypertension as defined by a sustained BP > 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter.
- Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501
- Has an active infection requiring systemic treatment
- Is participating in another therapeutic clinical trial
- Additional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b)
- Has known hypersensitivity to any component in the formulation of cemiplimab
- Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (>10 mg daily prednisone equivalent)
- Has a condition requiring systemic treatment with corticosteroids
Where it is running
- University of the Sunshine Coast Clinical Trials — Buderim, Queensland, Australia (enrolling)
- Tasman Oncology Research — Southport, Queensland, Australia (enrolling)
- Princess Alexandra Hospital | Metro South Health — Woolloongabba, Queensland, Australia (enrolling)
- St Vincent's Hospital — Darlinghurst, New South Wales, Australia (enrolling)
- Cancer Care Wollongong — Wollongong, New South Wales, Australia (enrolling)
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
- University of Texas Southwestern Medical Center — Dallas, Texas, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
- Southern Oncology Clinical Research Unit — Bedford Park, South Australia, Australia
- California Research Institute — Los Angeles, California, United States
- St John of God Subiaco Hospital — Subiaco, Western Australia, Australia
- BRCR Global — Tamarac, Florida, United States
- Gabrail Cancer Center Research — Canton, Ohio, United States
- Ohio State University — Columbus, Ohio, United States
- Allegheny Health Network — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.